Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Tesamorelin
EfficacyHigh
Studies8
Participants1,459
StatusAvailable

Tesamorelin

Growth Hormone-Releasing Hormone (1-44) amide

Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.

Complete Research Database

Clinical Research Outcomes

Clinical Outcome Measures

+18.7
Physical Function
(from 42.3 baseline)
+22.1
Self-Esteem
(from 38.9 baseline)
+15.4
Sexual Life
(from 35.2 baseline)
+24.8
Public Distress
(from 41.7 baseline)
+17.2
Work
(from 44.1 baseline)
Clinical outcome measures

Cardiovascular & Metabolic Outcomes

Blood Pressure Reduction

-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs

Triglycerides

-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement

HDL Cholesterol

+8.3% increase
Statistical significance: p<0.01
Improved lipid profile

Waist Circumference

-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity

C-Reactive Protein

-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation

Sleep Apnea Events

-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Tesamorelin (Egrifta) is an FDA-approved prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment requires proper patient selection, monitoring, and management of potential side effects. Patients must be evaluated for contraindications including active malignancy and diabetic complications. Regular monitoring of glucose levels, IGF-1, and treatment response is essential for safe and effective use.